These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1326 related articles for article (PubMed ID: 9520411)

  • 41. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
    Hsu H; Lacey DL; Dunstan CR; Solovyev I; Colombero A; Timms E; Tan HL; Elliott G; Kelley MJ; Sarosi I; Wang L; Xia XZ; Elliott R; Chiu L; Black T; Scully S; Capparelli C; Morony S; Shimamoto G; Bass MB; Boyle WJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3540-5. PubMed ID: 10097072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
    Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
    Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M; Gorny G; Galvin RJ; Oursler MJ
    J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
    Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
    J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
    Chikatsu N; Takeuchi Y; Tamura Y; Fukumoto S; Yano K; Tsuda E; Ogata E; Fujita T
    Biochem Biophys Res Commun; 2000 Jan; 267(2):632-7. PubMed ID: 10631114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).
    Gao YH; Shinki T; Yuasa T; Kataoka-Enomoto H; Komori T; Suda T; Yamaguchi A
    Biochem Biophys Res Commun; 1998 Nov; 252(3):697-702. PubMed ID: 9837769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone.
    Okada Y; Montero A; Zhang X; Sobue T; Lorenzo J; Doetschman T; Coffin JD; Hurley MM
    J Biol Chem; 2003 Jun; 278(23):21258-66. PubMed ID: 12665515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells.
    Chung H; Kang YS; Hwang CS; Moon IK; Yim CH; Choi KH; Han KO; Jang HC; Yoon HK; Han IK
    J Korean Med Sci; 2001 Dec; 16(6):769-73. PubMed ID: 11748360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
    Kanematsu M; Yoshimura K; Takaoki M; Sato A
    Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.
    Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T
    J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
    Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
    Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.